Abstract
Objective
The stratification of microsatellite instability (MSI) status assists clinicians in making treatment decisions for colorectal cancer (CRC) patients. This study aimed to establish a CT-based radiomics signature to predict MSI status in patients with CRC.
Methods
A total of 837 CRC patients who underwent preoperative enhanced CT and had available MSI status data were recruited from two hospitals. Radiomics features were extracted from segmented tumours, and a series of data balancing and feature selection strategies were used to select MSI-related features. Finally, an MSI-related radiomics signature was constructed using a genetic algorithm–enhanced artificial neural network model. Combined and clinical models were constructed using multivariate logistic regression analyses by integrating the clinical factors with or without the signature. A Kaplan–Meier survival analysis was conducted to explore the prognostic information of the signature in patients with CRC.
Results
Ten features were selected to construct a signature which showed robust performance in both the internal and external validation cohorts, with areas under the curves (AUC) of 0.788 and 0.775, respectively. The performance of the signature was comparable to that of the combined model (AUCs of 0.777 and 0.767, respectively) and it outperformed the clinical model constituting age and tumour location (AUCs of 0.768 and 0.623, respectively). Survival analysis demonstrated that the signature could stratify patients with stage II CRC according to prognosis (HR: 0.402, p = 0.029).
Conclusions
This study built a robust radiomics signature for identifying the MSI status of CRC patients, which may assist individualised treatment decisions.
Key Points
• Our well-designed modelling strategies helped overcome the problem of data imbalance caused by the low incidence of MSI.
• Genetic algorithm–enhanced artificial neural network–based CT radiomics signature can effectively distinguish the MSI status of CRC patients.
• Kaplan–Meier survival analysis demonstrated that our signature could significantly stratify stage II CRC patients into high- and low-risk groups.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Colorectal cancer (CRC) is driven by numerous genetic and epigenetic events, and it has the third-highest mortality rate worldwide [1]. Microsatellite instability (MSI) is a major oncogenic factor that is defined as the generalised instability of short tandem repeat DNA sequences (microsatellites), which occurs in approximately 15% of CRC cases. Many studies have confirmed that MSI is a promising biomarker for the diagnosis of Lynch syndrome diagnosis [2], for predicting the treatment response [3] and prognosis of CRC patients [4, 5].
The National Comprehensive Cancer Network guidelines recommend MSI testing for patients [6]. MSI can be detected using polymerase chain reaction (PCR) or immunohistochemistry (IHC) for mismatch repair (MMR) protein expression. However, an invasive biopsy may cause a potential risk of complications such as bleeding and bowel perfusion. More importantly, the degree of MMR protein expression detected at different biopsy locations may be underestimated or overestimated owing to tumour heterogeneity [7]. Therefore, it is necessary to seek a non-invasive method to provide additional diagnostic information pertaining to MSI status prior to the initiation of procedures and treatments [8].
Computed tomography (CT) is a common imaging method that plays an important role in CRC staging; however, it is considerably challenging for radiologists to assess MSI status based on macroscopic CT images. Radiomics, a method of extracting high-throughput qualitative features from routine medical radiologic images, has the potential to characterise tumour phenotypes and improve cancer diagnosis, prognosis, and response to therapy [9, 10]. Several studies have suggested that it is feasible to predict the MSI status of CRC using radiomics methods [11,12,13,14,15,16,17,18]. However, most previous studies had modest datasets (less than 200) and lacked independent external validation cohorts [14,15,16,17,18]. Additionally, data imbalance caused by the low incidence of MSI hinders accurate predictive analysis in real-world applications [19]. Although a 1:1 or 2:1 random matching method has been performed in several previous studies [13, 15,16,17,18], a possible selection bias might limit real-world applications [20]. Moreover, all previous studies focused only on assessing the value of radiomics for MSI status prediction and failed to provide further prognostic information.
In this study, we aimed to explore the potential diagnostic value of MSI status and prognostic stratification using a CT-based radiomics approach based on real-world data in CRC patients.
Materials and methods
Patients and data collection
This retrospective study was approved by the Institutional Review Board of Guangdong Provincial People’s Hospital and the First Affiliated Hospital of Chongqing Medical University. The requirement for informed consent forms was waived due to the retrospective nature of the study. Consecutive patients pathologically diagnosed with CRC were recruited from two participating hospitals between May 2005 and July 2019.
The inclusion and exclusion processes are illustrated in Fig. 1. Patients with CRC enrolled in hospital I were randomly stratified into two independent cohorts (70% of patients were enrolled in the training cohort and 30% in the internal validation cohort) according to MSI status, and patients in hospital II were included in the external validation cohort. Overall survival analysis was performed on hospital I data, considering sufficient follow-up.
The patients’ clinical data, including age, gender, tumour location, TNM stage, carcinoembryonic antigen (CEA), and Ki-67, were retrospectively reviewed and recorded from the medical record archives. Overall survival (OS) was defined as the time from surgery to death from any cause. Those who were alive at the time of the last follow-up were considered censored data.
Identification of MSI status
MSI status was assessed using IHC staining to detect the expression levels of MMR gene proteins (MLH1, MSH2, MSH6, and PMS2). The results were reviewed and confirmed by two pathologists with more than 10 years of experience in the diagnosis of abdominal disease. Patients were divided into MSI-L/microsatellite stability (MSS) and MSI-H groups: the former was positive for all four MMR proteins, while the latter included patients who were negative for any one of the MMR proteins.
CT image acquisition
CT images were obtained using six CT scanners from two institutions. All patients underwent enhanced abdominal CT scans. For hospital I, patients were examined using 8-slice (Lightspeed Ultra 8, GE Healthcare), 64-slice (LightSpeed VCT, GE Healthcare), or 256-slice (Brilliance iCT, Philips Healthcare) multidetector CT scanners. For hospital II, 64-slice (Somatom Sensation, Siemens Healthcare or LightSpeed VCT, GE Healthcare) or 128-slice (Discovery CT750, GE Healthcare) CT scanners were used to perform abdominal CT scans. The acquisition parameters of the two institutions were as follows: tube voltage, 120 keV; tube current, 130–250 mAs, collimation, 0.625–2.5 mm, slice thickness, 1–5 mm, reconstruction interval, 0.625–1.25 mm. The contrast agents were injected at a speed of 2.5–3.5 mL/s with a high-pressure pump syringe. Portal phase CT scans were performed 55–75 s after the injection of the contrast agents.
Image pre-processing and tumour segmentation
To minimise the centre effect of CT images from different scanners and hospitals [21], all original CT images were appropriately pre-processed. First, the images were resampled to 1 × 1 × 1 mm3 (x, y, z) using a linear interpolation algorithm to standardise the voxel spacing [22]. Then, a 25 HU bin width was set to discretise the voxel intensity and reduce the noise [23].
Tumours were segmented manually on the axial images at the portal venous phase by one radiologist with 10 years of experience with CRC diagnosis using ITK-SNAP software (version 2.2.0, www.itksnap.org), and mesentery air and pericolonic fat were excluded from the volume of interest (VOI) data. Another radiologist with 15 years of experience in abdominal disease evaluation revised and confirmed the segmentation results. Tumour VOIs were saved for subsequent quantitative feature extraction.
Radiomics feature extraction and standardisation
CT radiomics features of tumour VOI were automatically extracted using the PyRadiomics software package (version 3.0.1, https://pyradiomics.readthedocs.io/en/ latest/changes.html), which included shape, first-order, texture, wavelet, exponential, and square transform features [24].
ComBaTool and z-scores were then used to normalise the features. ComBaTool, a free online application (https://forlhac.shinyapps.io/Shiny_ComBat/) [25], was used to pool features and minimise inter-scanner variability [26]. Principal component analysis (PCA) was utilised to visualise the effects of Combat on feature uniformisation. Finally, all radiomics features were standardised using z-scores. The radiomics analysis process is shown in Fig. 2.
Radiomics feature selection
As illustrated in Fig. 3, a series of coarse-to-fine data balancing and feature selection strategies were performed to deal with the imbalanced dataset and dimensionality reduction (Fig. 3A–D). Initially, an independent-sample t-test or Mann-Whitney U test was performed to coarsely choose features with the statistical differences between the MSI-H and MSI-L/MSS groups. Then, the random under-sampling method generated K-balanced subsets with an equal number of MSI-H and MSI-L/MSS patients. A recursive feature elimination support vector machine (RFE-SVM) method was designed to recursively train these samples using a SVM model with the linear kernel function. Features with minimum weight were eliminated, and the top-ranking feature subset was retained. High-frequency features were then selected by counting the occurrences in the K features’ subsets. Subsequently, upsampling was performed to alleviate model bias to majority class, followed by backward stepwise logistic regression to further reduced the features. Finally, a post hoc correlation analysis was used to inspect the redundancy of the final selected features.
Construction of the MSI-related radiomics signature
Artificial neural network (ANN) models are widely popular owing to their strong ability to describe complex and non-linear problems. Genetic algorithm–enhanced ANN (GANN) (Fig. 3E) has the potential to accelerate the updating of network parameters, avoid local optimisation, and improve prediction accuracy [27, 28].
The GANN model consisted of an input layer (radiomics features), a hidden layer, and an output layer (MSI status). Sigmoid and tangent activation functions were employed in the hidden and output layers, respectively. To prevent overfitting, the fitness function of the GA was described as min{AUCtrain, AUCinter − validation}, and the best parameter result was decoded after repetitive generations of population selection, crossover, and mutation operators. The output of the optimal GANN model was converted into a radiomics signature.
Development and validation of the predictive models
Univariate and multivariate logistic regression analyses were performed to construct the predictive models. The candidate clinical factors were gender (male versus female), age (continuous), primary tumour location [left (splenic flexure to sigmoid) versus right (caecum to transverse colon) or rectum], CEA (continuous), and Ki-67 (continuous). Then, a combined model was built incorporating all significant predictive factors, and a clinical model was constructed using only significant clinical factors.
Statistical analysis
Chi-square, Fisher's exact, or Mann-Whitney U tests were performed on the clinical factors in the training, internal and external validation cohorts, and between the MSI-H and MSI-L/MSS groups. Receiver operator characteristic (ROC) curve and area under the curve (AUC) values were used to evaluate the performance of the radiomics signature and prediction models. The DeLong test was used to compare AUC differences.
To evaluate the prognostic stratification value of the radiomics signature, patients were classified into predicted MSI-H and MSI-L/MSS groups by maximising their Youden index values. Survival curves were plotted using the Kaplan–Meier method and compared using the log-rank test. The GANN was operated in the MATLAB 2018b toolbox (MathWorks). Statistical analyses were performed using R (version 4.1.1) and Python (version 3.7.3). p values < 0.05 were considered statistically significant.
Results
Patient characteristics
A total of 837 CRC patients with a MSI-H prevalence of 10.6% (42/396) in hospital I and 12.6% (56/441) in hospital II were included in the study. Table 1 shows the patients’ clinical information and a comparison between patients with MSI-H and MSI-L/MSS. No statistical differences were found among all factors expect tumour location (p < 0.001). No variable was significantly different between the training and internal validation cohorts (p = 0.122~1.000). Moreover, 99.2% (393/396) of patients were followed up for OS, and the median [Q25, Q75] OS was 65.5 [50.3, 76.2] months for hospital I.
Radiomics feature extraction, standardisation, and selection
A total of 1037 radiomics features were extracted (14 shape-based features, 18 first-order statistical features, 75 texture features, and 744 wavelet decomposition features, 93 exponentials, 93 square transform features) from the tumour VOIs. Figure 4a shows that the data distributions of the two centres were relatively scattered before eliminating the centre effects, whereas these were pooled together following normalisation using ComBat.
For feature selection, 590 features were coarsely selected by an independent-samples t-test or Mann-Whitney U test. Subsequently, 47 high-frequency features that appeared more than 15 times in 100 feature subsets were selected using random downsampling and RFE-SVM methods (Fig. 4b). Finally, 10 predictive features were determined using a backward stepwise logistic regression analysis (Fig. 4c). The correlation results between the features are shown in Fig. 4d.
Development and performance of the MSI-related radiomics signature
Ten radiomics features were employed as network input neurones, MSI statuses were employed as network output neurones, and the number of hidden neurones was set in a range of 1 to 9. Before training, MSI statuses were pre-processed by times two and minus one to fit the tangent activation function. The GANN model was built with the following parameters: maximum epochs, 500; generations, 300; and population size, 100. Initial population individuals were randomly generated. The other parameters were set as the default values.
The AUCs with different hidden neurones in the three cohorts are shown as three broken line graphs (Fig. 5a). After considering the overall performance of the different cohorts, the optimal structure was determined to be the GANN with five hidden neurones and AUCs of 0.792 (95% confidence interval [CI]: 0.706–0.873), 0.788 (95% CI: 0.671–0.888), and 0.780 (95% CI: 0.722–0.831), respectively. The detailed optimisation process is shown in Fig. 5b, and the distribution of the network weights and the proportions of radiomics features weights are visualised as a Sankey diagram (Fig. 5c).
Development and performance of the prediction models
Univariate and multivariate logistic analyses identified age, tumour location, and radiomics signature as independent predictors of MSI status, as detailed in Table 2. The combined model was constructed by combining all the above factors, while the clinical model was constructed with only age and tumour location.
The AUC, accuracy, sensitivity, and specificity of each model are presented in Table 3. The performance of the MSI-related radiomics signature (AUCs of 0.792, 0.788, and 0.775 in the training, internal, and external validation cohorts) was comparable to that of the combined model (AUCs of 0.806, 0.777, and 0.767; DeLong’s test, p = 0.746–0.920); it also outperformed the clinical model (AUCs of 0.747, 0.768, and 0.623, p < 0.001).
Prognostic analysis of the signature
Patients were divided into predicted MSI-L/MSS (signature < −0.01) or MSI-H (signature > −0.01) groups based on the signature cutoff value by maximising their Youden index values. Kaplan–Meier survival analyses (Fig. 6) showed that the signature could successfully stratify stage II CRC patients (HR: 0.402, 95% CI: 0.172–0.937; log-rank, p = 0.029) and predicted that patients with MSI-H had a significant prognostic advantage compared to MSI-L/MSS patients, while no statistical differences were found for stage I (p = 0.940) and III (p = 0.950) CRC patients.
Discussion
In this study, we applied a genetic algorithm–enhanced artificial neural network to establish an MSI-related radiomics signature based on 277 venous phase–enhanced CT images to predict the MSI statuses of CRC patients. Its performance was successfully verified in internal (119 patients) and external validation cohorts (441 patients). Meanwhile, we found that patients with stage II CRC with predicted MSI-H had better prognoses than those with MSI-L/MSS. The results indicate that the radiomics method is a feasible tool for assessing MSI status.
Although judged by AUC values, the performance of our radiomics signature was moderate compared to previous models [11,12,13,14,15,16,17,18] (AUCs of 0.775–0.792 versus 0.688–0.918, respectively); our model had a more robust performance when applied to the real-world data cohorts in our study. This might have resulted from the elimination of potential centre effects with the ComBat method and well-designed feature selection and modelling strategies applied to account for imbalanced data.
Unbalanced data distribution owing to the low incidence of MSI is a challenge for MSI status classification in real-world applications. Some previous studies used the synthetic minority oversampling technique (SMOTE) [16, 18] to create simulated MSI samples; however, this strategy made the model more likely to become overfitted. Another study proposed an initial bias adjustment method [12] for weighted MSI samples, but it was difficult to guarantee the generalisation ability. Bootstrapping is a recommended method for handling imbalanced medical image data [20]. In our study, a combination of bootstrapping and the RFE-SVM method was proposed to select high-frequency features, and an upsampling modelling strategy was adopted to alleviate model bias toward the majority class [29]. Moreover, a genetic algorithm was utilised to further improve the generalisation ability of the signature. This may be attributed to the fact that genetic algorithm is good at global searching, and the weight adjustment is also exquisite [30].
Our results demonstrate the feasibility of using CT radiomics features to predict CRC genetic information. Although the underlying mechanisms by which radiomics predicts MSI status remain unclear, we assumed that radiomics features could characterise tumour size and heterogeneity. Most studies have reported that MSI-H CRC showed a larger tumour size and more intra-tumoural heterogeneity than MSI-L/MSS tumours [31, 32]. Based on the feature weights in the signature, LeastAxisLength, Variance, and InverseVariance were ranked as the top three radiomics features. LeastAxisLength measures the length of the VOI-enclosing ellipsoid and represents the tumour size. Variance and InverseVariance are the measurements of image spatial heterogeneity, and larger values of variance and smaller values of InverseVariance reflect greater heterogeneity. According to the radiomics signature equation, tumours with larger sizes and more heterogeneity tended to be MSI-H, which is partly in agreement with the findings of Chaddad et al [33]. In contrast, MSI status is a prognostic biomarker, and patients with stage II MSI-H CRC have a lower risk of death [5]. Interestingly, we found that patients with stage II predicted MSI-H CRC (HR: 0.402, 95% CI: 0.172–0.937; p = 0.029) showed better outcomes than those with predicted MSI-L/MSS.
Moreover, clinical factors are associated with genetic alterations in tumours. Consistent with previous studies [34], our study identified that MSI-H CRC occurs predominantly in the younger population and on the right side. This may be explained by the fact that the proximal and distal colon have different embryonic origins, leading to distinct biological properties [35]. However, the addition of clinical factors to radiomics features did not significantly enhance our model’s prediction performance, which is in line with previous studies [36, 37]. This finding may be attributed to the fact that radiomics methods can capture heterogeneity differences among tumour locations and different genetic and epigenetic information, a function that overlaps with but is ultimately superior to clinical effects after employing powerful machine learning algorithms [38].
This study had some limitations. First, this was a retrospective study, which may have inevitably led to some information selection bias. Second, we focused only on the most commonly used CT images of the portal venous phase to develop the radiomics signature. Further work is needed to explore whether non-contrast and arterial phase images can provide more information for MSI status estimation. Third, CRC tumours were manually segmented, which is time-consuming and inevitably causes inter-observer variations. In future studies, an automated colorectal tumour segmentation method should be developed to resolve this issue. Finally, different scanners and acquisition parameters were used in our study, which may have influenced the radiomics features. However, significant efforts have been made to minimise the effects using ComBaTool and the z-scores method.
In conclusion, we constructed and validated a non-invasive radiomics signature based on routine clinical CT images to identify patients’ MSI statuses, and the signature could stratify patients with stage II CRC. These findings could potentially aid in clinical decision-making regarding personalised treatment for patients with CRC.
Abbreviations
- ANN:
-
Artificial neural network
- CEA:
-
Carcinoembryonic antigen
- CRC:
-
Colorectal cancer
- GANN:
-
Genetic algorithm–enhanced artificial neural network
- IHC:
-
Immunohistochemistry
- MMR:
-
Mismatch repair
- MSI:
-
Microsatellite instability
- MSI-H:
-
High MSI
- MSI-L:
-
Low MSI
- MSS:
-
Microsatellite stability
- PCA:
-
Principal component analysis
- PCR:
-
Polymerase chain reaction
- RFE:
-
Recursive feature elimination
- SVM:
-
Support vector machine
- VOI:
-
Volume of interest
References
Latham A, Srinivasan P, Kemel Y et al (2019) Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol 37:286–295
Wei Q, Ye Z, Zhong X et al (2017) Multiregion whole-exome sequencing of matched primary and metastatic tumours revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis. Ann Oncol 28:2135–2141
Nguyen M, Tipping Smith S, Lam M et al (2021) An update on the use of immunotherapy in patients with colorectal cancer. Expert Rev Gastroenterol Hepatol 15:291–304
Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138(6):2073–2087
Toh JWT, Phan K, Reza F, Chapuis P, Spring KJ (2021) Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: systematic review and meta-analysis. Int J Color Dis 36:1573–1596
Toh JWT, Singh P, Tangirala VAASK, Limmer A, Spring KJ (2021) A simple, accurate and cost-effective capillary electrophoresis test with computational methods to aid in universal microsatellite instability testing. Cells 10:1401
Yörüker EE, Holdenrieder S, Gezer U (2016) Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer. Clin Chim Acta 455:26–32
Marcuello M, Vymetalkova V, Neves RPL et al (2019) Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol Asp Med 69:107–122
Huang Y, Liang C, He L et al (2016) Development and validation of a radiomics nomogram for preoperative prediction of Lymph node metastasis in colorectal cancer. J Clin Oncol 34:2157–2164
Liu Z, Meng X, Zhang H et al (2020) Predicting distant metastasis and chemotherapy benefit in locally advanced rectal cancer. Nat Commun 11:4308
Pei Q, Yi X, Chen C et al (2022) Pre-treatment CT-based radiomics nomogram for predicting microsatellite instability status in colorectal cancer. Eur Radiol 32:714–724
Cao Y, Zhang G, Zhang J et al (2021) Predicting microsatellite instability status in colorectal cancer based on triphasic enhanced computed tomography radiomics signatures: a multicenter study. Front Oncol 11:687771
Li Z, Zhong Q, Zhang L et al (2021) Computed tomography-based radiomics model to preoperatively predict microsatellite instability status in colorectal cancer: a multicenter study. Front Oncol 11:666786
Li J, Yang Z, Xin B et al (2021) Quantitative prediction of microsatellite instability in colorectal cancer with preoperative PET/CT-based radiomics. Front Oncol 11:702055
Wu J, Zhang Q, Zhao Y et al (2019) Radiomics analysis of iodine-based material decomposition images with dual-energy computed tomography imaging for preoperatively predicting microsatellite instability status in colorectal cancer. Front Oncol 9:1250
Li Z, Dai H, Liu Y, Pan F, Yang Y, Zhang M (2021) Radiomics analysis of multi-sequence MR images for predicting microsatellite instability status preoperatively in rectal cancer. Front Oncol 11:697497
Golia Pernicka JS, Gagniere J, Chakraborty J et al (2019) Radiomics-based prediction of microsatellite instability in colorectal cancer at initial computed tomography evaluation. Abdom Radiol (NY) 44:3755–3763
Fan S, Li X, Cui X et al (2019) Computed tomography-based radiomic features could potentially predict microsatellite instability status in stage II colorectal cancer: a preliminary study. Acad Radiol 26:1633–1640
Bader-El-Den M, Teitei E, Perry T (2019) Biased random forest for dealing with the class imbalance problem. IEEE Trans Neural Netw Learn Syst 30:2163–2172
Parmar C, Barry JD, Hosny A, Quackenbush J, Aerts HJWL (2018) Data analysis strategies in medical imaging. Clin Cancer Res 24:3492–3499
Dissaux G, Visvikis D, Da-Ano R et al (2020) Pretreatment F-FDG PET/CT radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non-small cell lung cancer: a multicentric study. J Nucl Med 61:814–820
Ligero M, Jordi-Ollero O, Bernatowicz K et al (2021) Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis. Eur Radiol 31:1460–1470
Ji G-W, Zhu F-P, Xu Q et al (2020) Radiomic features at contrast-enhanced CT predict recurrence in early stage hepatocellular carcinoma: a multi-institutional study. Radiology 294:568–579
van Griethuysen JJM, Fedorov A, Parmar C et al (2017) Computational radiomics system to decode the radiographic phenotype. Cancer Res 77:e104–e107
Orlhac F, Lecler A, Savatovski J et al (2021) How can we combat multicenter variability in MR radiomics? Validation of a correction procedure. Eur Radiol 31:2272–2280
Da-Ano R, Masson I, Lucia F et al (2020) Performance comparison of modified ComBat for harmonisation of radiomic features for multicenter studies. Sci Rep 10:10248
Zhang Y, Gao X, Smith K et al (2019) Integrating water quality and operation into prediction of water production in drinking water treatment plants by genetic algorithm enhanced artificial neural network. Water Res 164:114888
Gong Y-J, Li J-J, Zhou Y et al (2016) Genetic learning particle swarm optimization. IEEE Trans Cybern 46:2277–2290
Krawczyk B (2016) Learning from imbalanced data: open challenges and future directions. Prog Artif Intell 5:221–232
Yu L, Jin W, Li X, Zhang Y (2018) Optimization of bioactive ingredient extraction from Chinese herbal medicine : a comparative study of three optimization models. Evid Based Complement Alternat Med 2018:6391414
Fujiyoshi K, Yamaguchi T, Kakuta M et al (2017) Predictive model for high-frequency microsatellite instability in colorectal cancer patients over 50 years of age. Cancer Med 6:1255–1263
Bai W, Ma J, Liu Y et al (2019) Screening of MSI detection loci and their heterogeneity in East Asian colorectal cancer patients. Cancer Med 8:2157–2166
Bogowicz M, Riesterer O, Ikenberg K et al (2017) Computed tomography radiomics predicts HPV status and local tumor control after definitive radiochemotherapy in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 99:921–928
Song Y, Wang L, Ran W et al (2020) Effect of tumor location on clinicopathological and molecular markers in colorectal cancer in Eastern China patients: an analysis of 2,356 cases. Front Genet 11:96
Bufill JA (1990) Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 113:779–788
Han Y, Xie Z, Zang Y et al (2018) Non-invasive genotype prediction of chromosome 1p/19q co-deletion by development and validation of an MRI-based radiomics signature in lower-grade gliomas. J Neuro-Oncol 140:297–306
Gong L, Xu M, Fang M et al (2020) Noninvasive prediction of high-grade prostate cancer via biparametric MRI radiomics. J Magn Reson Imaging 52:1102–1109
Sagaert X, Vanstapel A, Verbeek S (2018) Tumor heterogeneity in colorectal cancer: what do we know so far? Pathobiology 85:72–84
Funding
This study was supported by the Key-Area Research and Development Program of Guangdong Province [No. 2021B0101420006], the National Key Research and Development Program of China [No. 2021YFF1201003], the National Science Fund for Distinguished Young Scholars [No. 81925023], the National Natural Scientific Foundation of China [No. 82072090, 81901910, 81771912, and 81901909], Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application [No. 2022B1212010011], Funding by Science and technology Projects in Guangzhou [No. 202201020001, 202201010513], and High-level Hospital Construction Project [No. DFJHBF202105].
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Guarantor
The scientific guarantor of this publication is Xiaobo Chen.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
Xiaobo Chen, Lan He, and Xin Chen kindly provided statistical advice for this manuscript.
Informed consent
Written informed consent was waived by the Institutional Review Board.
Ethical approval
Institutional Review Board approval was obtained.
Methodology
• retrospective
• diagnostic or prognostic study
• multicentre study
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Chen, X., He, L., Li, Q. et al. Non-invasive prediction of microsatellite instability in colorectal cancer by a genetic algorithm–enhanced artificial neural network–based CT radiomics signature. Eur Radiol 33, 11–22 (2023). https://doi.org/10.1007/s00330-022-08954-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-022-08954-6